Navigation Links
Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Date:11/4/2008

ROCKVILLE, Md., Nov. 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 third quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on November 10, 2008. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on November 10, 2008. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 793-1308 International: (703) 639-1310.

A live audio webcast of the conference call will be available at http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EST. November 10, 2008 through midnight November 13, 2008. To access the replay, dial (888) 266-2081 and enter pass code 1290008.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategi
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
2. Novavax CEO to Present at BIO Investor Forum 2008
3. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
4. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
5. Novavax Announces Closing of $18 Million Registered Direct Offering
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. Novavax to Join Russell 3000 Index
8. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
11. Novavax Reports First Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., SAN DIEGO, Nov. 9 NexBio, Inc....9 annual American College of Allergy, Asthma, and ...s entitled "DAS181 (Fludase®), a Sialidase, D...lammatory Effects in Animal Models of Asthma". ,...broad spectrum host-targeting drug candidate being...
(Date:11/9/2009)... Product release is a resea...ubjects, research facilities and research safety s...n. , Cedar Knolls, NJ (PR...nounced today that it has unveiled Pristima™...r research facilities that track the use and care ...
(Date:11/8/2009)...,, MOUNTAIN VIEW, Calif. Nov. 5, 2009 Comple...ncing company, today announced publication of a re...ietary DNA sequencing platform, including analysis...s. The consumables cost for these three genomes se...arrays ranged from $8,005 for 87x coverage to $1,7...
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ ...), a biopharmaceutical company developing first-in... its financial results for the third quarter ended...py that, in September of this year, the FDA,s Arth...by a vote of 12-0, the approval of XIAFLEX(TM) for...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6
...auna Kea Technologies and VisualSonics today annou...ion agreement through which VisualSonics will mark...imaging systems to pre-clinical researchers on a w...rs with a new way to understand physiological phen...itu in animal subjects. For the first time, pre-cl...
...Nasdaq: IDMI ) today reported financial results ...r 31, 2008. Financial information presented repre... and its subsidiary, IDM Pharma S.A. , , Total re... $0.3 million, and net loss was $1.8 million or $0... the year ended December 31, 2008 were $3.1 millio...
...SHP,NASDAQ: SHPGY ), the global specialty biopha...n agreement with GlaxoSmithKline plc (NYSE: GSK ...sules CII with the aim of,improving recognition an...eement covers the United States and will more than...es effort for VYVANSE by adding over 600 sales,rep...
Other Biology Technology:VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 2VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 3IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6
(Date:11/4/2009)...tural science) , United States Using Less Wate...ay than it did 35 years ago, despite a 30 percent ...tly attributable to alternative cooling methods at...s. According to the latest USGS water use report, ... goes to cooling thermoelectric power plants. Irri...
(Date:11/4/2009)...teria, it turns out, hold the power to help milita... world clean up toxic waste on test sites. , Com... invented back in World War II and have been used ...rgy compounds are often used to propel tank shells... But with increased knowledge of their environmen...
(Date:11/4/2009)...., Oct. 19 Spectros, developer and...aging devices which shed light on life-threatening...usive distribution deals for both its T-Stat®...ered include Australia, New Zealand, The Netherla...y, France, Spain, Portugal, Poland, Greece, Turkey...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2VIVUS Announces Promotion of Peter Tam to President 5941 1VIVUS Announces Promotion of Peter Tam to President 5941 2VIVUS Announces Promotion of Peter Tam to President 5941 3MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 1MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 2MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 3Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 1Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 2
...the University of Michigan Medical School have dis...arly-onset form of kidney disease and renal failur...d phospholipase C epsilon or PLCE1. , Identifying ... PLCE1 affects the development of podocytes ?speci...s ability to remove waste products from blood, whi...
... the Université de Montréal has concluded that peo...r a night of studying will strongly hurt their rec...he current issue of Neuropsychopharmacology was co...f Psychology at the Université de Montréal. Dr. Ca...ital du Sacré-Coeur de Montréal. , "We already kn...
...al studies of the interactions between oscillating...the toughest questions in ecology, including the n...ing to an article in the December 2006 issue of Bi...niversity of Michigan, shows how extensions of est... populations oscillate in synchrony because of int...
Other Biology News:Mutant gene causes severe kidney disease in infants 2Mutant gene causes severe kidney disease in infants 3Mutant gene causes severe kidney disease in infants 4Negative effects of caffeine are stronger on daytime sleep than on nocturnal sleep 2
Peptone from Sigma-Aldrich
...2 cells were cultured in Minimum Essential Medium ... log phase of growth. In order to keep the antige...one-methanol. The cells are arrayed on a 12-well ...ace specifically treated to enhance cellular attac...
...ells were cultured in Minimum Essential Medium (Ea...g phase of growth. In order to keep the antigens ...-methanol. The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachme...
...Plus Microsphere/Microarray Stabilizer is an aqueo...n and other non-toxic chemicals in a PBS buffer (p...uct contains a combination of 0.02% methylisothiaz...e. StabilCoat Plus Stabilizer provides optimum pe...
Biology Products: